Dihydrazine Plus Tablet

Adult dosage

The usual dose for this medication is 50 mg of losartan potassium/12.5 mg of hydrochlorothiazide taken once daily. Doses exceeding 100 mg of losartan potassium/25 mg of hydrochlorothiazide per day are not desirable. 1. It is possible to switch to this medication from individually dosed losartan potassium and hydrochlorothiazide combination therapy. 2. For patients not controlled with monotherapy of losartan or hydrochlorothiazide, start with a regimen of 50 mg of losartan potassium/12.5 mg of hydrochlorothiazide taken once daily; if blood pressure remains uncontrolled after 3 weeks, the dose can be increased to a maximum of 100 mg of losartan potassium/25 mg of hydrochlorothiazide taken once daily. 3. For patients not controlled with 100 mg of losartan potassium monotherapy, start with a regimen of 100 mg of losartan potassium/12.5 mg of hydrochlorothiazide taken once daily; if blood pressure remains uncontrolled after 3 weeks, the dose can be increased to a maximum of 100 mg of losartan potassium/25 mg of hydrochlorothiazide taken once daily. 4. For patients who are not controlled on 25 mg of hydrochlorothiazide once daily, or who exhibit hypokalemia even at this dosage: The overall antihypertensive effect can be managed while reducing the hydrochlorothiazide dose by starting with a regimen of 50 mg of losartan potassium/12.5 mg of hydrochlorothiazide taken once daily. Thereafter, continue to measure clinical response to losartan potassium 50 mg/ hydrochlorothiazide 12.5 mg; if blood pressure remains uncontrolled after 3 weeks, the dose can be increased to a maximum of 100 mg of losartan potassium/25 mg of hydrochlorothiazide taken once daily. ○ In patients with kidney impairment Administer the usual dose if creatinine clearance is 30 mL/min or more. For more severe kidney impairment, the use of loop diuretics is preferred over thiazide drugs, so administration in such patients is not recommended. ○ In patients with liver impairment Administration of the initial dosage of 25 mg of losartan potassium in patients requiring dose adjustments is not possible due to this medication; hence use in these patients is not recommended. ○ In pediatric patients (under 18 years old) Due to a lack of experience in pediatric and adolescent usage, the combination of losartan-hydrochlorothiazide should not be administered to children and adolescents.

Children's dosage

Due to a lack of experience in pediatric and adolescent usage, the combination of losartan-hydrochlorothiazide should not be administered to children and adolescents.

This medication can cause serious injury or death to the fetus if taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. This medication should not be used in patients with specific diseases or conditions, such as anuria, severe liver impairment, severe kidney impairment, pregnant women or women of childbearing potential, and patients with certain genetic metabolic disorders. Use with caution in patients with various health conditions, such as hypotension, decreased kidney function, liver impairment, cerebrovascular disorders, and electrolyte imbalances, particularly in elderly patients or those with a history of diabetes or gout who require special attention. During treatment with this medication, regular monitoring of blood pressure, kidney function, and electrolyte levels is recommended to check for abnormalities, and if symptoms of electrolyte imbalance (e.g., muscle cramps, weakness, confusion) occur, immediate consultation with a healthcare provider is necessary. Due to hydrochlorothiazide, skin may become sensitive to sunlight, so exposure to ultraviolet light should be avoided, and new skin lesions should be reported to a doctor. This medication may interact with other drugs, so it is crucial to inform healthcare providers of any other medications being taken, especially potassium supplements or potassium-containing salt substitutes, which should not be taken without medical consultation. Caution is needed while driving or operating machinery due to potential dizziness or drowsiness, especially during the initial doses or when changing doses. There is limited experience with this medication in children and adolescents, hence it is not recommended for them; also, elderly patients may experience adverse reactions more frequently and should be monitored closely. Pregnant and breastfeeding women should consult a doctor as this medication may pose risks to the fetus and newborn. If breastfeeding, it is advisable to either discontinue breastfeeding or stop taking the medication. Overdose may result in symptoms like hypotension and tachycardia, and immediate medical attention should be sought for appropriate treatment. This medication should be stored in its original container and kept in a safe place out of reach of children.

Serious side effects

Hives, angioedema (including swelling of the lips and eyelids and facial rash), angioedema (including laryngeal/pharyngeal swelling that may obstruct the airway, swelling of the face/lips/pharynx/tongue), severe swelling, difficulty breathing, jaundice (including intrahepatic cholestatic jaundice), renal failure, anuria, severe skin reactions (such as mucocutaneous syndrome (Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell's syndrome), etc.) resulting in exfoliative dermatitis.

Mild side effects

Abdominal pain, swelling/edema, palpitations, back pain, dizziness, cough, sinusitis, upper respiratory infection, weakness/fatigue, diarrhea, nausea, headache, bronchitis, pharyngitis, chest pain, facial swelling, fever, orthostatic hypotension, fainting, angina, arrhythmia (atrial fibrillation, sinus bradycardia, tachycardia, ventricular tachycardia, ventricular fibrillation), cerebrovascular accident, hypotension, myocardial infarction, secondary AV block, loss of appetite, constipation, toothache, dry mouth, indigestion, gas, gastritis, vomiting.

This medication is sensitive to light and should be stored in a container that does not allow light in. It should also be kept in a sealed container to avoid contact with air, and storage temperature should maintain room temperature between 1°C and 30°C.

Appearance

Yellow oval film-coated tablet

Package unit

10 tablets/blister x 3, 300 tablets/bottle